Daewoong Pharmaceutical Co., Ltd (KRX:069620)

Market Cap	1.52T
Revenue (ttm)	1.49T
Net Income (ttm)	75.10B
Shares Out	11.51M
EPS (ttm)	6,526.75
PE Ratio	20.27
Forward PE	10.30
Dividend	600.00 (0.45%)
Ex-Dividend Date	Dec 27, 2024

Volume	102,986
Average Volume	40,490
Open	137,200
Previous Close	136,500
Day's Range	132,000 - 137,200
52-Week Range	109,000 - 174,500
Beta	0.51
RSI	38.29
Earnings Date	Nov 14, 2025

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,644
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2024, Daewoong Pharmaceutical's revenue was 1.42 trillion, an increase of 3.44% compared to the previous year's 1.38 trillion. Earnings were 24.73 billion, a decrease of -79.68%.